IFNA1 and Zika virus infectious disease: A vaccine to protect against ZIKV infection, transmission and pathogenesis is a challenge that requires deep molecular and cell/tissue knowledge on how the virus infects and persists through several cell types and organs, particularly, in immune privileged tissues where vaccines should induce IFN-mediated innate antiviral immunity, and recruit long-term memory cellular and humoral protective immunity.